Recently long non-coding RNAs (lncRNA) have emerged as new gene regulators and prognostic markers in several cancers including renal cell carcinoma (RCC). In this study, we investigated the contributions of the lncRNA MALAT1 in RCC with a specific focus on its transcriptional regulation and its interactions with Ezh2 and miR-205. We found that MALAT1 expression was higher in human RCC tissues where it was associated with reduced patient survival. MALAT1 silencing decreased RCC cell proliferation and invasion and increased apoptosis. Mechanistic investigations showed that MALAT1 was transcriptionally activated by c-Fos and that it interacted with Ezh2. After MALAT1
INTRODUCTION
Renal cell carcinoma (RCC) is one of the 10 most common cancers and it is estimated that there were 63,920 new cases of RCC in the United States in 2013 (1) . The incidence of renal cell carcinoma has increased for over two decades (2) and patients with advanced RCC (stage IV) have a significantly reduced five-year survival rate (less than 30%) (3).
Compared to other cancers, there are very few tumor and biomarkers for renal cancer (4).
Also, renal cancer patients respond poorly to conventional chemotherapy and radiation treatment (5), thus early detection and treatment are very important for RCC patients.
Human genome sequence data indicates that more than 90 % of the DNA sequence is actively transcribed but only 2% of it encodes protein, thus the majority of transcripts are referred to as non-coding RNAs (ncRNAs) (6, 7) . Based on size, non-coding RNAs are divided into two groups, small non-coding RNAs and long non-coding RNAs greater than 200 nt (lncRNA). Small non-coding RNAs such as microRNAs have been studied extensively and their roles in gene regulation and cell function have been elucidated in numerous cancers (7) . Recent studies have shown that lncRNAs play important roles in both normal development and diseases including cancer (8) . LncRNAs participate in several different biological processes including epigenetic regulation, nuclear import, cell cycle control, nuclear and cytoplasmic trafficking, imprinting, cell differentiation, alternative splicing, RNA decay, transcription and translation (9, 10). Thus long non-coding RNAs have emerged as new players in cancer research and several studies have shown that some lncRNAs function as oncogenes, tumor suppressor genes or both, depending on the circumstance (11) .
Several lncRNAs [GAS5, MEG3 (=GTL2), HIF-1alpha-AS1, H19, KCQN1OT1, MALAT1
(alpha-gene), and HOTAIR] have been reported to be involved in renal cancer (12) (13) (14) (15) (16) (17) (18) (19) . MALAT1 (alternative name "alpha gene") is located on chromosome 11q13 and the expression of MALAT1 has been reported to be up-regulated in several cancers including lung, breast, pancreas, liver, colon, uterus, cervix and prostate (10) . Previous papers showed that MALAT1 expression is an independent prognostic parameter for survival in several cancers (10) . Davis et al has reported that chromosomal translocation of t (6; 11) (p21; q13) was observed in pediatric renal cancer, resulting in the fusion of the alpha gene (MALAT1) with TFEB, a basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factor (17) .
Kuniper et al has reported that the bHLH-LZ transcription factor TFEB gene on chromosome 6 is fused to the anonymous non protein encoding Alpha gene (MALAT1) on chromosome 11 through chromosomal translocation, t(6;11)(p21;q13) in papillary RCC (18) .
In this study we focused on lncRNA MALAT1 in clear cell RCC since the majority of adult renal cancers are of the clear cell type and many studies have focused on clear cell RCC. The aim of this study was to: 1) determine the role of MALAT1 in renal cancer, 2) determine the reason for MALAT1 overexpression in renal cancer tissues, 3) determine the downstream effects of MALAT1 in renal cancer and 4) determine the association between MALAT1 and microRNA-205 in renal cancer. 
MATERIALS AND METHODS

Clinical Samples
A total of 50 patients (34 male and 16 female) with pathologically confirmed clear cell RCC (cc-RCC) were enrolled in this study (Toho University Hospital, Tokyo, Japan). The mean age of the patients was 60.2 (range 37-77). They were classified according to the WHO criteria and staged according to the tumor-node-metastasis (TNM) classification.
Information about the patients is shown in Table S1 . Samples were obtained from the patients after written informed consent was obtained at Toho University hospital.
Cell culture
Normal renal epithelial cells (HK-2; ATCC number: CRL-2190) and renal cancer cell lines Total RNA, DNA and protein extraction RNA (microRNA and total RNA) was extracted from formalin-fixed, paraffin-embedded (FFPE) human renal cancer and adjacent non-cancerous normal kidney tissues using a miRNeasy FFPE kit (QIAGEN, Valencia, CA, USA) after micro-dissection based on a pathologist's reviews. To digest DNA, the Qiagen RNase-Free DNase kit was used. RNA (microRNA and total RNA) was also extracted from human cell lines using a miRNeasy mini kit (QIAGEN). Genomic DNA was extracted from cell lines using a QIAamp DNA (20) . Clear cell RCC is the major histologic subtype (about 80% of RCC cases) and inactivation of the VHL tumor suppressor gene is typical in ccRCC (20) .
We also found that high c-Fos overexpression was associated with shorter overall survival of RCC patients (data not shown). Thus we focused on c-Fos as a potentially important transcription factor in MALAT1 activation.
Construction of luciferase expressing plasmid vector containing the MALAT1 promoter region
Based on several computer algorithms as described above, we identified potential binding sites for transcription factor c-Fos in the promoter region of MALAT1 gene. Using 786-O genomic DNA, the identified MALAT1 promoter DNA region was amplified and the polymerase chain reaction products were cloned into the pGEM-T easy vector System (Promega) ( Table S2) . Then the MALAT1 promoter DNA region was incorporated into the pGL4 luciferase expression vector (Promega). Luciferase activity was assessed using the Dual-Luciferase® Reporter Assay System (Promega) (48 hours after their transfection) and the ratio of Firefly/Renilla luciferase activity was determined.
Overexpression of transcription factor genes (c-Fos)
In order to construct transcription factor gene (c-Fos) over expressing plasmids, the gene was amplified with total RNA from human adult normal kidney tissues (catalog#: R1234142-50, Biochain Institute, Newark, CA, USA) by transcription-polymerase chain reaction (RT-PCR) as described previously (21) . The sequences of primers for cloning are shown in Table S2 .
TCF/LEF reporter assay (TOPflash luciferase assay)
TOPflash luciferase assays were performed to assess the knock down effect of MALAT1 on the Wnt-beta catenin signaling pathway as described previously (21) .
RNA immunoprecipitation (RIP) Assay
RNA immunoprecipitation (RIP) was performed to investigate whether ribonucleoprotein RT-qPCR and shown as fold enrichment of MALAT1. The RIP RNA fraction Ct value was normalized to the input RNA fraction Ct value.
ChIP assay
ChIP assays were performed on cell line DNA using an Imprint Chromatin Immunoprecipitation Kit (Sigma-Aldrich). Antibody for trimethyl-Histone H3 (Lys27) (H3K27-me3) (catalog#07-449, EMD Millipore, Billerica, MA, USA) was obtained from Table S2 .
Immunohistochemistry study
Immunostaining of E-Cadherin was performed on formalin-fixed, paraffin-embedded (FFPE) specimens using rabbit polyclonal antibody against human E-Cadherin (#3195, Cell
Signaling Technology, Beverly, MA). The TaqMan probes and primers were purchased from Applied Biosystems. Human GAPDH and RNU48 were used as endogenous controls. Levels of RNA expression were determined using the 7500 Fast System SDS software version 1.3.1 (Applied Biosystems).
Western analysis
Western blot was performed as described previously. The antibodies used were specific for 
Statistical analysis
All statistical analyses were performed using StatView (version 5; SAS Institute Inc., NC). between cFos mRNA expression and MALAT1 mRNA or MALAT1 mRNA and Ezh2 mRNA in human renal cancer tissues was examined with two sided Pearson's correlation (22) . Statistical significance was determined using the Students t-test or Analysis of Variance (ANOVA) for functional analysis. A p-value of < 0.05 was regarded as statistically significant.
RESULTS
Relationship between MALAT1 expression and clinical characteristics
Initially we compared MALAT1 expression in 16 matched normal kidney and renal cancer tissues (all cc-RCC) using real-time RT-PCR. MALAT1 expression was significantly higher in all renal cancer tissues compared to matched normal kidney tissues (Fig. 1A) . We then used 50 renal cancer samples and divided the RCC patients into two groups using a median MALAT1 2^-delta Ct value of 0.1485 (Fig. 1B) . Next we investigated the association of (Table S1 ). Over-all survival was also significantly shorter in the high MALAT1 expression group compared to the low MALAT1 group (Fig. 1C) .
Effect of MALAT1 on renal cancer cell viability, invasion and apoptosis
As shown in Figure 2A , the knock down effect was best using si-MALAT1 (No.1) compared to si-MALAT1 (No.2). Thus we used si-MALAT1 (No.1) for further experiments.
As shown in Figure 2 , we observed significantly decreased cell viability (Fig. 2B) and invasion ( Fig. 2C) 
transfected cells. The percent of apoptotic cells was significantly increased in si-MALAT1 transfected cells (Fig. 2D) .
c-Fos expression in normal kidney and renal cancer tissues
Expression of transcription factor c-Fos mRNA was significantly higher in renal cancer tissues compared to those in matched normal kidney tissues (Fig. 3A) .
Positive correlation between c-Fos and MALAT1 expression
As shown, there was significant positive correlation between c-Fos mRNA and MALAT1 mRNA expression (Two sided Pearson's correlation, r=0.6643, p<0.0001) (Fig. 3B) .
MALAT1 expression was also significantly increased after c-Fos overexpression in 786-O cells ( Fig. 3C and Fig. 3D) . To investigate the direct binding of c-Fos to the MALAT1 promoter, we constructed luciferase vectors containing potential c-Fos binding sites (clone 1; clone 2) (Fig. 3E) . The clone 1 luciferase vector contained two potential c-Fos binding sites and clone 2 contains one binding site. As shown in Figure 3F , luciferase activity was significantly increased in c-Fos transfected cells compared to control vector with the two constructs (Fig. 3F) .
Signaling cross-contribution of transcription factors, MALAT1 and Ezh2 in RCC
Some lncRNAs are activated transcriptionally (23) (24) (25) (26) and several reports have shown that lncRNA HOTAIR binds to Polycomb repressive complex2 (PRC2) (Ezh2, Suz12, EED) enhancing methylation of H3K27me3, resulting in gene silencing (27) . Several long non-coding RNAs such as H19 and EBIC have been found to bind to Ezh2 in other cancers (28, 29) . MALAT1 has been reported to bind to Suz12, a component of PRC2 in bladder cancer cell lines (30) . These papers indicated that the interaction between MALAT1 and Ezh2 might be important for this study. We have made a schematic diagram illustrating (Fig. 4A) .
Ezh2 expression in renal cancer and normal kidney tissues
Ezh2 mRNA expression was significantly higher in renal cancer tissues compared to normal kidney tissues (Fig. 4B) .
Positive correlation between MALAT1 mRNA and Ezh2 mRNA expression
We compared the mRNA expression levels for both MALAT1 and Ezh2 in renal cancer tissues and found that there was significant positive correlation between the two groups (Two sided Pearson's correlation, r=0.595, p<0.0001) (Fig. 4C) .
Association of Ezh2 with clinicopathological parameters in RCC tissues
The expression of Ezh2 was significantly higher in pT (pT3+pT4) and pN (+) patients compared to those in pT1+pT2 and pN (-) patients (Table S4) . Over-all survival was also significantly shorter in the high Ezh2 expression group compared to the low Ezh2 group (Fig. 4D ).
MALAT1 and Ezh2expression in renal cancer cells and a normal kidney cell line
MALAT1 expression was significantly higher in renal cancer cell lines (A-498 and 786-O)
compared to that in normal kidney cell line HK-2 (Fig. 4E) . Ezh2 mRNA expression was also significantly higher in renal cancer cell lines (Fig. 4E) compared to normal kidney cells.
RNA immunoprecipitation (RNA-IP)
Some lncRNAs affect expression of protein coding genes by interacting with Polycomb repressive complex2 subunit Ezh2 (27) . To investigate potential interaction between lncRNA MALAT1 and Ezh2, RNA-IP was performed. We found that MALAT1 was (Fig. 4F) .
Effect of MALAT1 on downstream effectors in renal cancer cell
After knock down of MALAT1, expression of Ezh2, beta-catenin and c-Myc protein was significantly decreased in RCC cell lines while in contrast E-Cadherin protein expression was significantly increased (Fig. 5A) . E-Cadherin mRNA expression was low in renal cancer cells (A-498 and 786-O) compared to HK-2 cells (Fig. S1 ) and E-Cadherin protein expression was also significantly lower in renal cancer tissues (Fig. 5B) . There was also inverse correlation between E-Cadherin protein and MALAT1 mRNA expression in renal cancer tissues (Fig. 5C) . Since Ezh2 is an enhancer of H3K27 methylation, we used ChIP analysis using anti-H3K27 me3 antibody to determine the effect of si-MALAT1 on histone modification in the E-Cadherin gene promoter. The histone associated DNAs that were immunoprecipitated with antibody against H3K27-me3 were individually amplified with primers sets covering the E-Cadherin gene promoter regions. The level of H3K27-me3 was significantly decreased by MALAT1 knock down compared to control cells (Fig. 5D) .
Since total beta-catenin expression was significantly decreased by knock down of MALAT1, we looked at the nuclear fraction and found that nuclear beta-catenin was also significantly decreased (Fig. 5E) . TCF reporter activity (TOPflash) was also significantly decreased by MALAT1 knock down in both renal cancer cell lines (Fig. 5F) .
Interaction between MALAT1 and miRNA-205 in renal cancer
We also investigated the potential relationship between lncRNA MALAT1 and microRNA. (Fig. 6A) . Knock down of MALAT1 significantly increased miR-205 expression in renal cancer cells (Fig.   6B) , however after overexpression of miR-205 (Fig. 6C) , MALAT1 expression was significantly decreased (Fig. 6D) . These results suggest that interaction between MALAT1 and miRNA-205 has reciprocal effects.
Discussion
LncRNA MALAT1 (metastasis associated in lung adenocarcinoma transcript 1) has been reported to be up-regulated in many cancers (33) . Initially we looked at MALAT1 mRNA expression in matched normal human kidney and renal cancer tissues and found that MALAT1 expression was significantly higher in renal cancer tissues (all samples: ccRCC). genomic integration of RNA destabilizing elements (48) which may be useful to silence lncRNA expression in cancer patients. A limitation of the current study is lack of in vivo experiments such as an orthotopic animal model using siRNA or sh-RNA for MALAT1 knock down which may be useful to help the molecular mechanism involved in RCC invasion and metastasis. Future studies using a large cohort of samples from renal cancer patients will be required to establish a strong correlation between MALAT1 expression and renal cancer clinic-pathological characteristics as well as help identify potential clinical application in RCC patients.
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